You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ichthammol

Showing 26 - 50 of 66
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Los Angeles (Bortezomib, Dexamethasone, Pelareorep)

Not yet recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Los Angeles, California
  • +1 more
Aug 19, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in United States (drug, biological, other)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Des Moines, Iowa
  • +8 more
Jan 12, 2023

Advanced Malignant Tumor, Fatigue, Metastatic Malignant Tumor Trial in Houston (drug, behavioral, other)

Active, not recruiting
  • Advanced Malignant Neoplasm
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Mar 3, 2022

Plasmacytoma, POEMS Syndrome Trial in Rochester (Dexamethasone, Ixazomib Citrate, Lenalidomide)

Active, not recruiting
  • Plasmacytoma
  • POEMS Syndrome
  • Rochester, Minnesota
    Mayo Clinic in Rochester
May 26, 2022

Breast Carcinoma Trial in United States (Dexamethasone, Laboratory Biomarker Analysis, Netupitant/Palonosetron Hydrochloride)

Recruiting
  • Breast Carcinoma
  • Honolulu, Hawaii
  • +17 more
May 17, 2022

Metastatic Malignant Tumor in the Brain, Metastatic Malignant Solid Tumor Trial in Atlanta (drug, procedure, radiation)

Recruiting
  • Metastatic Malignant Neoplasm in the Brain
  • Metastatic Malignant Solid Neoplasm
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Aug 13, 2021

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Seattle (Carfilzomib, Chemosensitivity Assay,

Terminated
Has Results
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
May 6, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Columbus (Bortezomib, Daratumumab and Hyaluronidase-fihj,

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 30, 2021

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (Carfilzomib, Dexamethasone, Pomalidomide)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jun 3, 2022

Plasma Cell Leukemia, Plasma Cell Myeloma, Plasmacytoma Trial in Rochester, Nashville (Dexamethasone, Ixazomib Citrate,

Active, not recruiting
Has Results
  • Plasma Cell Leukemia
  • +2 more
  • Rochester, Minnesota
  • +1 more
May 19, 2022

Plasma Cell Myeloma Trial (Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone)

Not yet recruiting
  • Plasma Cell Myeloma
  • (no location specified)
Dec 22, 2022

Recurrent Plasma Cell Myeloma Trial in Columbus (Dexamethasone, HDAC Inhibitor AR-42, Laboratory Biomarker Analysis)

Completed
  • Recurrent Plasma Cell Myeloma
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Jun 10, 2021

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Jacksonville (Dexamethasone, Ibrutinib, Laboratory

Suspended
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Jacksonville, Florida
    Mayo Clinic in Florida
Mar 22, 2022

Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Rochester (biological, drug, other)

Recruiting
  • Plasma Cell Myeloma
  • +2 more
  • Belantamab Mafodotin
  • +4 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jun 10, 2022

Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis Trial in Houston

Recruiting
  • Newly Diagnosed Primary Amyloidosis
  • +2 more
  • Daratumumab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 12, 2021

Dyspnea, Malignant Tumor Trial in Houston (Dexamethasone, Placebo, Questionnaire Administration)

Active, not recruiting
Has Results
  • Dyspnea
  • Malignant Neoplasm
  • Houston, Texas
  • +2 more
Nov 29, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Houston (Bendamustine Hydrochloride, Carfilzomib,

Completed
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Bendamustine Hydrochloride
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 7, 2021

Recurrent Primary Amyloidosis Trial in United States (drug, biological, other)

Active, not recruiting
  • Recurrent Primary Amyloidosis
  • Duarte, California
  • +4 more
Mar 10, 2021

Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Houston (drug,

Terminated
Has Results
  • Multiple Myeloma-Light Chain Only
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2021

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Indianapolis, Rochester, Wauwatosa (Bortezomib,

Withdrawn
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Indianapolis, Indiana
  • +2 more
Sep 29, 2020

DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma Trial in Seattle

Completed
Has Results
  • DS Stage I Plasma Cell Myeloma
  • +3 more
  • Seattle, Washington
    Fred Hutchinson Cancer Research Center/University of Washington
Oct 29, 2019

Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma Trial in United States (drug,

Recruiting
  • Plasma Cell Myeloma
  • +2 more
  • Anchorage, Alaska
  • +459 more
Dec 7, 2022

Indolent Plasma Cell Myeloma, Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma Trial in Rochester (biological, drug, other)

Completed
Has Results
  • Indolent Plasma Cell Myeloma
  • +2 more
  • Anakinra
  • +4 more
  • Rochester, Minnesota
    Mayo Clinic
Mar 13, 2020

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, CNS Lymphoma, Intraocular

Completed
  • B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
  • +5 more
  • Scottsdale, Arizona
  • +6 more
Jul 18, 2019

Smoldering Plasma Cell Myeloma Trial in United States (biological, drug, other)

Recruiting
  • Smoldering Plasma Cell Myeloma
  • Daratumumab
  • +4 more
  • Anchorage, Alaska
  • +595 more
Dec 7, 2022